Seeking Alpha

Mylan (MYL -0.6%) says its subsidiary, Mylan Pharmaceuticals, has received final FDA approval...

Mylan (MYL -0.6%) says its subsidiary, Mylan Pharmaceuticals, has received final FDA approval for its Abbreviated New Drug Application for Candesartan Cilexetil and Hydrochlorothiazide Tablets, the generic version of AstraZeneca's (AZN) Atacand HCT, which is indicated indicated for the treatment of hypertension. Mylan will begin shipping all approved strengths immediately.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|